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Herpes	simplex	virus	type	1	(HSV-1)	not	only	causes	painful	recurrent	oral-labial	infections,	it	can	also	cause	
permanent	brain	damage	and	blindness.	There	is	currently	no	HSV-1	vaccine.	An	effective	vaccine	must	stimu-
late	coordinated	T	cell	responses,	but	the	large	size	of	the	genome	and	the	low	frequency	of	HSV-1–specific	
T	cells	have	hampered	the	search	for	the	most	effective	T	cell	antigens	for	inclusion	in	a	candidate	vaccine.	
We	have	now	developed	what	we	believe	to	be	novel	methods	to	efficiently	generate	a	genome-wide	map	of	
the	responsiveness	of	HSV-1–specific	T	cells,	and	demonstrate	the	applicability	of	these	methods	to	a	second	
complex	microbe,	vaccinia	virus.	We	used	cross-presentation	and	CD137	activation–based	FACS	to	enrich	for	
polyclonal	CD8+	T	effector	T	cells.	The	HSV-1	proteome	was	prepared	in	a	flexible	format	for	analyzing	both	
CD8+	and	CD4+	T	cells	from	study	participants.	Scans	with	participant-specific	panels	of	artificial	APCs	identi-
fied	an	oligospecific	response	in	each	individual.	Parallel	CD137-based	CD4+	T	cell	research	showed	discrete	
oligospecific	recognition	of	HSV-1	antigens.	Unexpectedly,	the	two	HSV-1	proteins	not	previously	considered	
as	vaccine	candidates	elicited	both	CD8+	and	CD4+	T	cell	responses	in	most	HSV-1–infected	individuals.	In	
this	era	of	microbial	genomics,	our	methods	—	also	demonstrated	in	principle	for	vaccinia	virus	for	both	CD8+	
and	CD4+	T	cells	—	should	be	broadly	applicable	to	the	selection	of	T	cell	antigens	for	inclusion	in	candidate	
vaccines	for	many	pathogens.
Introduction
Herpes simplex virus type 1 (HSV-1) infects 60% of the US pop-
ulation and has a significant cumulative health care burden in 
addition to causing painful recurrent oral-labial infections. For 
example, brain and eye infections can cause permanent damage 
or blindness (1). HSV-1 also causes approximately 50% of clinical 
first-episode genital herpes in the United States. Vaccines for HSV 
that have been tested thus far have failed in clinical trials, includ-
ing a recent phase III trial of an adjuvanted glycoprotein D (gD2) 
product (2). This vaccine elicits antibody and CD4+ T cell responses 
but fails to induce CD8 responses. Newer platforms can elicit CD8+ 
and CD4+ cells, but they require rationally selected T cell antigens. 
We therefore developed methods to permit measurement of both 
CD8 and CD4 responses to the complete HSV-1 proteome to begin 
rational prioritization of next-generation vaccine candidates.
Several recent observations support the concept that an effec-
tive HSV vaccine will need to induce coordinated CD8+ and CD4+ 
T cell responses. HSV-1–specific CD8+ T cells localize to the site 
of HSV-1 infection in human and murine trigeminal ganglia (TG) 
(3–5), and both HSV-specific CD8+ and CD4+ T cells localize to 
acute and healed sites of skin infection in mice and humans, sug-
gesting that optimally programmed memory cells could monitor 
for infection or reactivation (6–8). In animals, HSV ganglionic 
load correlates with reactivation frequency, so pre-equipping an 
individual with HSV-specific CD8+ T cells could reduce seeding 
of the ganglia, even if a primary infection occurs in recipients of a 
non-sterilizing vaccine, and ameliorate the chronic disease (9, 10). 
Strong CD8+ responses can be protective in HSV infection–spe-
cific mouse models (11). In murine protection models based on 
attenuated live virus or DNA vaccines, protection is more typically 
CD4 dependent, and in humans, HSV disease worsens with CD4 
depletion in untreated human immunodeficiency virus type 1 
(HIV-1) infection (12, 13).
The breadth and specificity of HSV-1–specific T cells in humans 
is largely unknown. The virus has a large, 152-kb genome encoding 
about 77 polypeptides (14, 15). BenMohamed et al. demonstrated 
A*0201-restricted responses to HSV-1 glycoprotein D (16, 17). 
A limited number of CD8 epitopes discovered in the context of 
HSV-2 research are sequence identical and thus cross-reactive with 
HSV-1. In HSV-1–infected human eyes, we have demonstrated 
CD4 reactivity with proteins in the viral tegument encoded by 
genes UL21, UL46, UL47, and UL49 (18–23). Envelope glycoproteins 
gD1 and gB1 are also known CD4 antigens (24).
The rules governing CD8 specificity are an important issue for 
HSV vaccine design. HSV genes are expressed in sequential, coor-
dinated kinetic waves during the viral replication cycle, and a sub-
set of proteins are present in virions and injected into cells upon 
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viral entry. Some replication-incompetent whole HSV vaccines are 
blocked at the DNA replication step, such that true late proteins, 
which are only made after DNA replication, are not expressed (25). 
Other strains have a later replication block, with true late proteins 
being synthesized in the cytoplasm of infected cells (26). This 
property is shared by attenuated but replication-competent can-
didates (27). One of our goals was therefore to determine whether 
the CD8 response is weighted toward any specific kinetic or struc-
tural subset of HSV-1 proteins.
HSV immune evasion and the low abundance of HSV-specific 
CD8+ cells in human blood have made the study of HSV-specific 
T cell responses difficult. Inhibition of transporter associated with 
antigen presentation (TAP), downregulation of HLA class I (28, 29), 
decreased DC co-stimulation (30), and disruption of TCR signal-
ing (31, 32) mediated by various HSV genes all likely contribute 
to difficulties with direct presentation in in vitro settings. In con-
trast, murine HSV data show that both the priming of naive CD8 
responses and the recall of memory CD8+ cells use cross- rather 
than direct priming and presentation (33–38). We have previously 
shown that human monocyte-derived DCs (moDCs) can cross-
present HSV-2 to memory HSV-2–specific CD8s (39). In this report, 
we harnessed cross-presentation to stimulate HSV-1–specific CD8+ 
T cells, while CD4+ memory cells were reactivated with whole killed 
antigen. CD137 was then used to radically enrich HSV-1–specific 
T cells. CD137 is a tumor necrosis factor receptor family protein 
that identifies recently activated CD4+ and CD8+ T cells (40–42). A 
near complete collection of HSV-1 molecular clones was deployed 
in specific CD8 and CD4 formats to perform genome-wide scans 
of these polyclonal virus-specific T cells. Our data identified the 
proteins expressed by HSV-1 genes UL39 and UL46, previously not 
known to be CD8+ T cell antigens, as rational vaccine candidates for 
the elicitation of coordinated CD8 and CD4 responses. In contrast, 
gD1, the homolog of gD2, was a poor CD8 antigen.
To test the broad applicability of our methods, we evaluated 
vaccinia virus, a microbe with more than 200 genes. We studied 
whether moDC cross-presentation and CD137-based methods 
using whole virus would enrich vaccinia-reactive CD8+ and CD4+ 
T cells. The affirmative results suggest that a modular approach to 
T cell antigen discovery and prioritization, modified on a case-by-
case basis to reflect the biology of specific microbes, should be lat-
erally transferable to challenging pathogens with large genomes.
Results
HSV-1–specific CD8+ T cells can be detected and enriched by cross-presen-
tation. We studied 7 HSV-1–seropositive individuals (Table 1), in 
whom we measured HSV-1–specific T cell responses in fine detail. 
In each case, exposure of CD8+ cells from PBMCs to autologous, 
HSV-1 antigen–loaded moDCs for 20 hours resulted in detect-
able CD137 responses among live CD3+CD8+ cells (representative 
participant, Figure 1A). We observed that specific expression of 
CD137 was usually somewhat higher than for IFN-γ (Table 2). 
Among 3 individuals seronegative for HSV-1 and HSV-2 (indi-
viduals 12–14, Table 1), two had very low CD137 and cytokine 
CD8 responses, while participant 13 had detectable responses in 
both assays (Table 2).
An advantage of using CD137 to detect HSV-1–reactive CD8+ 
cells is the ability to sort and expand these cells for downstream 
testing. Sorted, polyclonal CD3+CD8+CD137hi cells and control 
CD3+CD8+CD137lo cells were expanded with a nonspecific mito-
gen. Resultant bulk populations were tested using autologous 
APCs infected by HSV-1. Significant proportions of the sorted, 
expanded CD137hi cells selectively recognized the infected APCs 
(representative data for participant 1 after 2 cell expansions in 
Figure 1B; all individuals in Table 3), while the CD137lo cells were 
nonreactive. Cytotoxicity was used to assess the antiviral effector 
function of the sorted, expanded cells. Brisk, self-restricted killing 
was noted for most participants (Table 3).
Detection and HLA restriction of HSV-1 antigen–specific CD8+ T cells. 
We cryopreserved more than 108 responder cells/individual and 
interrogated their responses with panels of artificial APCs (aAPCs), 
expressing one of the participant’s HLA-A, -B, or -C molecules, 
and specific fragments of HSV-1 genetic material. Full-length 
genes or fragments, together covering a total of 74 HSV-1 ORFs, 
were cloned into a custom vector suitable for expression in aAPCs. 
Table 1
Participants studied in this report
ID	 Age	 Sex	 HSV-1A	 HSV-2A	 HLA-AB	 HLA-B	 HLA-C	 HLA-DRB1	 HLA-DRB3,4,5	 HLA-DQB1
1 29 M pos neg *01xx, *0201 *5101, *5801 *0202, *07:01:01G *0701  *0202
2 42 F pos pos *01xx, *26xx *07xx, *08xx *0702/0750, *07:01:01G *1501, *0301 3*0301, 5*0101 *0602, *0201
3 24 F pos pos *2902, *6801 *1516, *4402 *0704/0711, *1402 *0401 *1101 3 pos, 4 pos *0301
4 42 F pos pos *2901, *6801 *3503, *4402 *04:01:01G1, *0704/0711 *0401, *1104 3 pos, 4 pos *0301, *0302
5 44 M pos pos *01xx, *0201 *08xx, *51xx *0102, *07:01:01G *0101, *0301 3 pos *0201, *0501
6 36 M pos pos *0201, *24xx *0305,  *04:01:01G *1104, *1401 3 pos *0301, *0503
      *3503/3570
7 40 M pos pos *0220, *0224 *4402, *0702 *0501/0503, *0702/0750 *0101, *0701 4 pos *0201, *0501
8 29 F pos neg Not done     
9 29 F pos neg Not done     
10 20 F pos neg Not done     
11 20 F pos neg Not done     
12 55 M neg neg *02xx *51xx, *60xx *01xx, *03xx *0101, *1501 5 pos *0501, *0602
13 45 F neg neg Not done     
14 50 M neg neg *02xx,  *38xx, *39xx *12xx *16xx, *11xx 3 pos, 5 pos *03xx, *05xx
     *6601/6604
AAt time of phlebotomy. BHLA nomenclature at A and B according to the older system (92); the newer system is used for HLA-C (73) (see Methods). The 
presence or absence of a functional allele at the HLA-DRB3, 4, and 5 loci is indicated for some individuals, and the alleles are identified for others.
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Transfection efficiency for HLA class I was typically 5%–20% at 48 
hours (data not shown). Transfection efficiencies for the HSV-1 
constructs were typically at least 10% (Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI60556DS1) as monitored with EGFP.
We completed CD8 ORFeome scans for every HLA-A, -B, and -C 
in 7 HSV-1–infected individuals (Table 1). T cell activation was 
monitored by IFN-γ secretion after addition of polyclonal CD8 
responders to the co-transfected aAPCs. Due to near-homozygos-
ity in one participant per locus, some participants had one scan at 
HLA-A, -B, or -C. We used 21 distinct HLA class I cDNA molecules 
in all. The most frequently studied alleles were A*0201 (4 individu-
als) and A*0101, B*4402, and Cw0701 (3 individuals each).
We observed discrete IFN-γ responses with very low backgrounds. 
A representative set of genome-wide screens for participant 1 (Fig-
ures 2, 3, and4) showed that each HLA allele had discrete CD8 reac-
tivities. For example, genes UL39 and UL48 had strong reactivity 
restricted by HLA-A*0101, confirmed with synthetic peptides includ-
ing two distinct epitopes in the UL48-endoded protein (Figure 5). 
Overall, there were 122 reactive combinations of HLA class I mol-
ecules and HSV-1 ORFs (Figure 6). The number of CD8 ORF-level 
hits per person ranged from 10 to 27, with a median of 17 and 
mean ± SD of 17 ± 7. Among these CD8 ORF-level hits, HLA-A 
was the most frequently used locus and HLA-C the least, with a 
mean ± SD of 10 ± 4.0, 6.6 ± 4.0, and 1.3 ± 1.7 CD8 ORF-level hits 
at the A, B, and C loci, respectively. All 6 HLA-A alleles and 6 of 7 
HLA-B alleles had one or more responses, while 3 of the 8 HLA-C 
alleles (0102, 0402, and 0704) did not. Overall, 28 of the 39 (72%) 
genome-wide screens yielded one or more reactive HSV-1 ORFs, with 
a range from 0 to a maximum of 13 for HLA-A*3503 in participant 
6, and a mean ± SD of 5.2 ± 2.3, 3.5 ± 3.8, and 0.6 ± 1.0 CD8 ORF-
level hits in individual HLA-A, -B, and -C allele screens, respectively.
HSV-1 ORFs eliciting CD8 responses enriched by cross-presentation. 
Overall, 40 distinct HSV-1 polypeptides were found to elicit CD8+ 
IFN-γ responses among the 7 participants. This represents 54% 
of the 74 unique proteins studied (Figure 6). These proteins had 
diverse expression kinetics, structural, and functional roles, as 
briefly annotated (Supplemental Table 2) and detailed in the pri-
mary literature (reviewed in ref. 1). Each immediate early protein 
expressed with α kinetics was represented, except for ICP47, a short 
polypeptide, as were early, leaky late, and true late polypeptides. 
Nonstructural proteins and structural proteins in the capsid, tegu-
ment, and envelope were all targeted by CD8+ T cells. The most 
population-prevalent CD8 antigen was encoded by UL39. This 
1,137-amino-acid-long polypeptide is the large subunit of ribo-
nucleotide reductase, is not detected in virions, and is a virulence 
Figure 1
Use of CD137 to detect and 
enrich HSV-1–specific CD8+ T 
cells from blood. (A) Gated live, 
CD3+ lymphocyte forward/side 
scatter window cells analyzed 
for CD8 and CD137 after admix-
ture of selected CD8+ cells with 
autologous moDCs loaded with 
mock- or HSV-1–infected HeLa 
cell debris (see Methods). Num-
bers are percentages of cells 
in indicated quadrants. Data 
for HSV-1–infected participant 
1 and HSV-uninfected partici-
pant 12 are shown. Small boxes 
indicate approximate gates for 
FACS. (B) Reactivity of par-
ticipant 1 polyclonal expanded 
responder cell line derived from 
CD3+CD8+ CD137hi or CD137lo 
cells after exposure to mock- 
or HSV-1–infected autologous 
B-LCLs or control stimuli for 18 
hours. Responder cells were 
initially gated using dump-gat-
ing of CFSE-labeled APCs 
(data not shown) and for CD3 
and CD8 (left), and analyzed for 
intracellular IFN-γ. Numbers are 
percentages of cells in indicated 
quadrants. iono, ionomycin.
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factor in vivo but dispensable in vitro. UL39 was recognized in 11 
of the 39 screens, in 6 of the 7 individuals, and was restricted by 7 
distinct HLA alleles: A*0101, A*0201, A*2402, A*6801, B*3503, 
B*5801, and Cw0202. The next most prevalently recognized 
protein was encoded by the abundant virion structural protein 
VP11/12, which is encoded by UL46. This protein is nonessential 
in vitro (1). UL46 was recognized in 10 screens and 5 participants 
and also restricted by 7 distinct alleles: A*0101, A*0201, A*2402, 
A*2601, A*2902, B*4402, and B*5101.
CD8 responses to HSV-1 proteins gD1 and gB1 were of special 
interest because they share high sequence homology with HSV-2 
proteins that have been used as vaccine candidates (2, 43–45). HLA-
A*0201–restricted CD8 epitopes have been previously reported in 
both HSV-1 and HSV-2 (16, 17). Both proteins were well expressed 
in the pEXP103 system (Supplemental Figure 2, A and B). Two of 
39 HLA-level screens showed reactivity with gD1 (Figure 6), for 
either HLA-B*1516 or HLA-B*3503. Among the 4 individuals 
with HLA-A*0201 or a close variant, none had A*0201-restricted 
responses to gD1. We additionally tested polyclonal HSV-reac-
tive CD8+ T cell lines from these individuals with three previously 
reported (16) A*0201-restricted synthetic peptides in gD that 
are sequence-identical in HSV-1 and HSV-2. Responses were not 
detected (Supplemental Figure 2C). In contrast, we 
demonstrated CD8 recognition of gB1 by 6 distinct 
HLA alleles and in 4 of 7 individuals.
Definition of HSV-1 peptide epitopes recognized by CD8+ 
T cells enriched by cross-presentation. To test for the pres-
ence of discrete peptide epitopes, we selected a subset 
of the CD8 antigens (Figure 6) that used HLA alleles 
with high population prevalence and had well-devel-
oped peptide binding prediction algorithms. We tested 
peptides from 24 distinct HSV-1 ORFs for potential 
HLA-A*0101–, -A*0201–, -A*2402–, -A*2902–, or 
-B*0702–restricted peptide epitopes. Bulk CD137hi-
selected CD8+ cells were tested for IFN-γ expression by 
intracellular cytokine cytometry (ICC) using autolo-
gous PBMCs as APCs. DMSO negative control gave very 
low background, such that tight groupings of IFN-γ+ 
CD8+ T cells could be discerned for antigenic peptides 
(representative data, Figure 5; full data, Supplemental 
Figure 3). Overlapping reactive 9- and 10-mer peptides 
were tallied as a single novel epitope. Overall, we defined 
45 distinct HSV-1 CD8 epitopes (Table 4) in 22 ORFs. 
Several reactive ORFs had more than one constituent 
CD8 peptide epitope (Table 4).
CD8 responses in direct PBMC assays. The CD8+ T cell line data above 
are qualitative rather than quantitative. The enrichment afforded 
by cross-presentation and cell selection could detect responses 
that were below the limit of detection in direct PBMC samples, 
and there is also the possibility we were detecting in vitro priming 
by moDCs. Epitope-specific responses in direct PBMC assays can-
not represent in vitro priming and are amenable to detailed phe-
notypic studies using tetramers and ICC. We therefore used IFN-γ 
ELISPOT to survey and rank epitope-specific responses for further 
studies. PBMCs from 20 HLA-appropriate individuals with HSV-1 
infection were matched with CD8 peptide epitopes with known 
HLA restriction. We tested 40 of the 45 CD8 epitopes (Table 4) 
as detailed in Methods. The participants included the discovery 
cohort (Table 1) and 13 additional HSV-1–infected individuals. 
Each individual had a strong IFN-γ response to whole UV HSV-1 
antigen (likely CD4+ cells) and no spot-forming units (SFU) for 
DMSO negative control (data not shown).
Among 256 HLA-matched combinations of PBMCs and HSV-1 
peptides in the overall set, 23 (9.0%) were positive (red cells with 
integers in Figure 7). Twelve of 20 (60%) individuals had from 1 to 
5 peptide-specific responses in direct PBMC testing. Among the 40 
Table 2
Direct ex vivo expression of intracellular IFN-γ or surface CD137 by live, 
CD3+CD8+ cells after cross-presentation by autologous moDCs loaded  
with HSV-1 or control antigen
	 IFN-γ	 CD137
Individual	 Mock	 HSV-1	 Net	 Mock	 HSV-1	 Net
HSV-seropositive
1 0.08 0.59 0.51 0.54 1.68 1.14
2 Not done Not done Not done 0.12 2.63 2.51
3 0.07 0.11 0.04 0.22 1.93 1.71
4 0.01 0.10 0.09 0.12 0.52 0.40
5 0.01 0.19 0.18 0.51 0.78 0.27
6 0.16 2.54 2.38 0.21 2.96 2.75
7 0.07 0.19 0.12 0.23 1.52 1.29
HSV-seronegative
12 0.07 0.08 0.01 0.32 0.50 0.18
13 0.24 0.78 0.54 0.48 2.29 1.81
14 0.05 0.03 –0.02 0.14 0.14 –0.01
Table 3
Recognition of HSV-1 by polyclonal, twice mitogen-expanded CD3+CD8+ PBMCs selected on the basis of CD137 expression  
after cross-presentation of HSV-1 by moDCs
	 IFN-γ	expression	in	response		 Cytotoxicity	against	autologous		 Cytotoxicity	against	allogeneic	
	 to	autologous	B-LCLs	±	HSV	infection	 B-LCLs	±	HSV	infection	 B-LCLs	±	HSV	infection
Person	 Mock	 HSV-1	 Mock	 HSV-1	 HSV-2	 Mock	 HSV-1	 HSV-2
1 0.5 45.6 –1.5 52.8 1.5 9.7 –1.3 8.5
2 0.2 4.4 2.7 16.5 0.8 10.2 4.9 4
3 0.4 4.6 1.6 46.1 2.4 4.3 3.6 5.6
4 0.4 14.8 –0.6 53.9 0.2 2.7 3.4 3.6
5 0.3 4.4 –0.2 8.9 –2.8 14.8 0.4 –3.4
6 0.5 16.1 5.8 16.8 –4.3 –3.2 8.1 –0.2
7 2.4 8.4 1.8 55.9 9.2 26 1.6 8.3
technical advance
658	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 122   Number 2   February 2012
CD8 peptide epitopes tested, 12 (30%) were positive in 1 or more 
HLA-matched individuals. The number of net IFN-γ ELISPOT+ 
cells ranged from 11 to 136 SFU/106 PBMCs. The highest rate of 
positivity was for the HLA-A*0201 peptides, with 6 of 9 epitopes 
positive in at least 1 individual, and 2 individuals positive for 4 
distinct A*0201 peptides. The “hits” in the HLA-ORF screens that 
were confirmed by direct PBMC testing were biologically present 
above the threshold of the direct ELISPOT test. Some individuals 
with positive ORF-level responses in HLA-specific screens (red in 
Figure 6) did not react with the peptides tested (blue in Figure 7). 
Peptide-reactive cells could be present below the limit of detection 
ex vivo. Alternatively, one or more undiscovered HLA-restricted epi-
topes accounted for the ORF-level positive responses (Figure 6).
HSV-1 ORFs stimulating population-prevalent CD4 responses. As 
noted above, measurement of unmanipulated PBMCs is limited 
by the low frequency of HSV-1–reactive CD4+ cells and the need 
for highly purified recombinant proteins or a very large peptide 
set. We therefore enriched and expanded HSV-1–reactive CD4+ 
Figure 2
Representative data from participant 1 (Table 1) for CD8+ T cell reactivity with HSV-1 ORFs and peptides. IFN-γ secretion by polyclonal 
expanded responder cell line derived from CD3+CD137hi cells exposed to aAPCs expressing the indicated HLA-A molecules and the 
HSV-1 ORFs arrayed in nominal genomic order on the x axis. The names of HSV-1 ORFs driving two representative positive responses 
are indicated for HLA-A*0101.
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T cells using protocols designed to yield large numbers of 
polyclonal responder cells. The initial stimulation used whole, 
cell-associated, UV-killed HSV-1, a format previously shown 
to restimulate CD4+ T cells specific for a variety of structural 
and nonstructural proteins in the context of HSV-2 (46). After 
20 hours, a small percentage of live CD3+CD4+ cells in PBMCs 
specifically expressed CD137 (representative participant, Figure 
8A). Cell lines created by sort purification and expansion with 
nonspecific mitogens were highly enriched for HSV-1–reactive 
CD4+ cells, while sorted CD137lo cells were nonreactive (Figure 
8A shows data after 2 cell expansions; enrichment was similar 
after the first expansion, data not shown).
We expressed proteins covering the large majority of the HSV-1 
proteome (Supplemental Table 1) using an in vitro bacterial 
expression system. Anti–6-His IB showed specific staining (data 
not shown). We titered the ORFeome set in preliminary prolifera-
tion assays and found that a dilution of 1:5,000 it gave optimal 
responses with low background (data not shown). We further 
Figure 3
Representative data from participant 1 (Figure 2 and Table 1) for CD8+ T cell reactivity with HSV-1 ORFs and peptides. IFN-γ secretion by 
polyclonal expanded responder cell line derived from CD3+CD137hi cells exposed to aAPCs expressing the indicated HLA-B molecules and the 
HSV-1 ORFs arrayed in nominal genomic order on the x axis.
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checked potency and identity with a CD4+ T cell clone specific for 
HSV-1 protein VP22 (gene UL49) (18) and noted strong, specific 
responses (Supplemental Figure 4).
Polyclonal CD137hi CD4+ cell lines showed discrete patterns of 
reactivity when assayed against the protein set (representative par-
ticipant, Figure 8B) in each of 11 individuals, including those with 
detailed CD8 studies (Table 1). The average number of HSV-1 ORFs 
recognized per individual was 22.8 ± 7.0 (mean ± SD). Overall, 52 of 
the 74 (70%) unique HSV-1 polypeptides were recognized at least 
once. On a population basis, the most prevalent CD4 responses were 
noted for envelope glycoproteins gB1 and gD1, and tegument pro-
tein VP11/12, encoded by gene UL46, discussed above for CD8+ cells. 
Each was recognized by 11 of 11 individuals (100%). Inspection of 
the overlap between CD8 and CD4 antigens (Figure 9) showed that 
the proteins encoded by UL39 and UL46 were frequently recognized. 
Grouping of HSV-1 proteins by their kinetics of expression during 
viral replication (1) indicates that true late proteins are less com-
monly recognized by CD8+ cells than are proteins in other classes.
Figure 4
Representative data from participant 1 (Figures 2 and 3 and Table 1) for CD8+ T cell reactivity with HSV-1 ORFs and peptides. IFN-γ secretion 
by polyclonal expanded responder cell line derived from CD3+CD137hi cells exposed to aAPCs expressing the indicated HLA-C molecules and 
the HSV-1 ORFs arrayed in nominal genomic order on the x axis.
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Application to vaccinia virus. Participant 9 from a previous report 
(47) was re-vaccinated with vaccinia 20 months prior to phleboto-
my. Using cross-presentation for CD8+ T cells, followed by CD137 
detection outlined exactly as done for HSV-1, we detected low but 
specific CD8 reactivity at 20 hours. Selected, expanded CD137hi but 
not CD137lo cells were highly enriched in vaccinia virus–specific 
CD8+ T cells (Figure 10A), and these cells had specific cytotoxicity 
(Figure 10B). Participant 8 (47), who had been re-vaccinated 40 
months prior to study, was studied for CD4 responses. We used 
UV-inactivated whole vaccinia virus and CD137-based selection, 
again as detailed for HSV-1. The CD137hi-origin bulk cells were 
very highly enriched for T cells making IFN-γ with or without IL-2 
in response to vaccinia, while these were essentially absent from 
CD137lo cells (Figure 10C). All cell populations responded to the 
positive control PMA/ionomycin stimulation, albeit with varying 
cytokine patterns. Similar results were obtained for several vac-
cinia-immune individuals. The CD8+ and CD4+ T cell enrichment 
methods (outlined in Figure 11) are thus applicable to two large-
genome microbes. Downstream CD4 analyses showed responses 
to discrete vaccinia ORFs (unpublished observations).
Discussion
HSV-1 is an important human pathogen, but there are no vac-
cines in active clinical development. In this report, we have shown 
that the proteins encoded by HSV-1 genes UL39 and UL46 have 
coordinated CD8 and CD4 immunogenicity in most individuals 
and are therefore rational vaccine candidates. We have provided 
an estimate of the complexity of the response, documented clus-
tering of responses based on HLA type, and defined more than 
40 novel CD8 T cell epitopes. We have identified a new hierarchy 
of responses based on HLA locus, with HLA-A more frequently 
responsible for antigen presentation than HLA-B, and HLA C hav-
ing a minor contribution. Parallel studies determined that infected 
humans recognize a mean of 17 and 23 HSV-1 ORFs as CD8 and 
CD4 antigens, respectively. With the exceptions noted in the Intro-
duction and Results, to our knowledge, the vast majority of the 
antigenic reactivities and epitopes we have defined are novel. We 
also showed applicability to another large-genome virus and antic-
ipate that these systems may be useful for many pathogens.
T cell responses to pathogens have been difficult to access for 
several reasons. Microbe-specific T cells can occur at low abun-
dance in the blood, such that an unbiased pre-enrichment step 
is helpful for new antigen or epitope discovery. Sylwester et al.’s 
probe of the response to the CMV proteome using peptides and 
direct PBMC ICC was enabled by the high overall abundance of 
T cell responses to CMV (48). Responses to EBV are also large, such 
that a direct PBMC approach to CD8 responses using a cloned par-
tial ORFeome has yielded hits (49). Indeed, the low magnitude of 
direct PBMC IFN-γ ELISPOT responses to single HSV-1 peptides 
in the current report contrast with the high-magnitude responses 
to single epitopes noted in CMV and EBV (48, 50).
We have shown that restimulation methods tailored for CD8+ 
or CD4+ T cells, based on the biology of antigen presentation, can 
be used without change for two distinct viruses. Once responder 
cells are enriched and expanded, the large microbial genomes still 
harbor myriad potential epitopes that are challenging to decode. 
In this report, we first assigned CD8 reactivity at the level of HSV-1 
ORFs, using efficient plasmid sets. Limited use of peptide binding 
algorithms and peptide synthesis efficiently confirmed antigenic-
ity to the epitope level. The new, validated peptide reagents were in 
turn positive in a proportion of additional HLA-appropriate sub-
jects in direct ex vivo assays. Even in our limited study population, 
CD8+ T cells from different individuals frequently had reactivity, 
in our primary co-transfection screens, with the same HSV-1 ORFs 
when studied using shared HLA cDNA molecules. For example, 
each HLA-A*0101–bearing donor had CD8+ T cells recognizing 
the HSV-1 ORFs UL1 and UL48 (Figure 6). Clustering studies to 
measure this tendency will be the subject of future analyses.
In addition to identifying UL39 and UL46 as rational candidate 
subunit vaccines, our data have implications for the design of 
whole virus formats. In fact, the diversity of the CD8 response, 
with an average of 17 antigens per person, implies that a whole 
virus rather than a subunit approach to vaccination for HSV-1 
is most likely to mimic the immune response to natural infec-
tion. Globally, we found that broad kinetic and structural and 
functional spectra of HSV-1 proteins were recognized by the 
human CD8 response. Therefore, either replication-incompetent 
or attenuated replication-competent vaccine formats have the 
potential to stimulate broad CD8 responses in most individu-
als. Among whole HSV vaccine candidates that replicate discon-
tinuously in normal cells, those that allow expression to proceed 
relatively completely may be quite rational (25, 26). To explore 
the virological rules of HSV-1 T cell antigenicity, we scored each 
protein dichotomously for CD8 responses in the study popula-
tion, and then categorized each protein studied as immediate 
early, early, late but not otherwise characterized, early late with 
Figure 5
Representative analyses of polyclonal HSV-1–reactive CD8+ cells from the same individual represented in Figures 2–4 probed for reactivity 
with individual HSV-1 peptides derived from the ORFs indicated below the plots, or negative or positive controls (Mock and SEB). Numbers are 
percentages of cells in the upper-right quadrants.
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synthesis prior to DNA replication, or true late with expression 
only after DNA replication (1). We also recorded, for each HSV-1 
protein, its absence, detection at less than 1%, or detection at 
greater than 1% of adjusted virion mass using mass spectroscopy 
data of purified virions (51). These analyses disclosed a weighting 
of CD8 responses toward HSV-1 proteins expressed prior to HSV-1 
DNA replication, and toward abundant virion polypeptides. Spe-
cifically, only 3 of 17 true late proteins (18%) were recognized by 
CD8+ cells. In contrast, 4 of 5 immediate early proteins (80%), 9 
of 12 early proteins (75%), 12 of 19 early late proteins (63%), 12 
of 20 late proteins not specified as early or late (60%), and 0 of 1 
proteins with no specified expression kinetics (0%) were CD8 anti-
gens (highlighted in Supplemental Figure 5 using Figure 9 data 
and expression classifications from a standard text; ref. 1). Among 
the more abundant virion proteins, 17 of 23 (74%) were positive 
for CD8 responses. In contrast, only 23 of 51 (45%) proteins either 
absent from virions or present at levels less than 1% were CD8 
antigens. The population prevalence for CD4 responses did not 
segregate by HSV-1 kinetics or structural class. Our data suggest 
that whole-virus HSV-1 format vaccines that express most pro-
teins normally made prior to DNA synthesis, or that can be dosed 
to provide a large mass of virion input proteins, should retain the 
potential to stimulate broad CD8 responses.
A vaccine covering HSV-1 and HSV-2 would be desirable. Half 
of the minimal HSV-1 CD8 epitopes defined in this report are 
sequence-identical in HSV-1 and HSV-2 and appropriate for 
candidate type–common vaccines. Indeed, the HSV-2 homologs 
of three epitopes — HLA-A*0101/HSV-1 UL39 512–520, HLA-
A*0201/HSV-1 UL25 367–375, and HLA-A*0201/HSV-1 UL27 
448–456 — were found in our prior HSV-2 work (52–54). HSV 
CD8 epitopes can also tolerate amino acid substitutions, as exem-
plified by UL46 354–362 of HSV-1 and HSV-2, differing at amino 
acid 2, and by ICP0 HSV-1 698–706 and its homolog HSV-2 ICP0 
742–750, differing at amino acids 1 and 3. It is certainly possible 
that cross-reactive T cells could be involved in cross-protection 
against some aspects of HSV-2 infection or severity observed in 
HSV-1–infected individuals (55). Most of our subjects were dually 
infected with both HSV types. Future cross-sectional studies com-
paring immune responses to HSV-1 in the presence or absence of 
HSV-2 coinfection could clarify the extent to which each infection 
contributes to the cross-reactive repertoire.
With regard to effector function, we showed that bulk HSV-spe-
cific CD8+ T cells enriched using cross-presentation and CD137 
have brisk virus-specific cytotoxicity. We plan to enrich peptide-
specific CD8+ cells with peptides (56) or tetramers (57) and study 
recognition of HSV-1–infected skin cells to more closely mimic 
physiologic target cells. The Cos-7 system has not been character-
ized for use in CTL assays, so we will move to a viral infection sys-
tem. In HSV-2 studies, T cells recognizing diverse antigens were 
able to lyse HSV-infected skin cells, but the specific conditions, 
such as the dose and time of infection and the requirement for de 
novo viral protein synthesis or for IFN-γ pretreatment (56, 58), dif-
fered between epitopes. With the larger panel of HSV-1 epitopes, 
we hope to establish general rules for CD8 recognition of physi-
ologically relevant cells that could inform vaccinology. Future 
cross-sectional study of populations with defined levels of HSV-1 
severity and longitudinal research during the ontogeny of primary 
Figure 6
HLA allele– and HSV-1 ORF-level IFN-γ immune signature of CD8+ 
cells in PBMCs of 7 individuals infected with HSV-1. Participant identi-
ties are listed below the figure. Each column represents an individual 
HLA-ORFeome screen. The HLA-A, -B, or -C alleles used are indi-
cated at the top. Each row represents the integrated data for an HSV-1 
ORF, with ORFs listed in nominal genomic order from RL1 (encoding 
γ34.5 protein) at top to RS1 (encoding protein ICP4) at bottom, with 
gene names from GenBank NC_001806.1. A red cell shows that spe-
cific IFN-γ secretion was detected for the intersecting HLA allele and 
HSV-1 ORF. Data for ORFs expressed as more than one fragment or 
exon are simplified to a yes/no call. UL36 amino acid coverage was 
partial (see Discussion). Black arrows indicate, from top to bottom, 
genes UL39, UL46, and US6.
Figure 7
Graphical summary of direct PBMC IFN-γ ELISPOT. HSV-1 peptides from Table 4 (n = 40, detailed in Methods) were tested with PBMCs from 
20 individuals with HSV-1 infection. Each column represents one participant; 1–7 are detailed in Table 1. Each row lists a peptide with 1 or more 
positive ELISPOT results. Green cells represent possible reactivities based on the participant bearing an HLA allele corresponding to the peptide 
tested, but for which the ORFeome screen with the listed HLA allele and ORF, and peptide ELISPOT, were negative. Blue cells are similar, but 
the ORFeome screen was positive and the peptide ELISPOT with the indicated peptide was negative. Red cells represent ORFs for which both 
the ORFeome screen with the listed HLA allele and ORF, and the ELISPOT for at least one peptide in the ORF, were positive. Numbers in red 
cells are positive ELISPOT results in units of net IFN-γ SFU/106 PBMCs.
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Table 4
HSV-1 CD8 epitopes and HSV-2 homologs
HLA	alleleA	 ORFB	 HSV-1	aaC	 HSV-1	sequenceC	 HSV-2	sequenceD	 HSV-2	aaD	 TC/TSD
A*0101 UL1 66–74 LIDGIFLRY R-------- 66–74 TS
A*0101 UL39 512–520E YMESVFQMY --------- 517–525 TC
A*0101 UL41 259–268 HTDLHPNNTY ---------- 261–270 TC
A*0101 UL46 354–362E ATDSLNNEY -S------- 354–362 TS
A*0101 UL47 360–368 RSSLGSLLY --------- 363–371 TC
A*0101 UL47 566–574 FTAPEVGTY S-------- 569–577 TS
A*0101 UL48 90–99 SALPTNADLY -GF-----M- 88–97 TS
A*0101 UL48 479–488 FTDALGIDEY ----M---DF 479–488 TS
A*0101 UL53 201–209 ETDPVTFLY -A------- 201–209 TS
A*0201 UL13 389–397 TLLELVVSV	 -----L--- 389–397 TS
A*0201 UL25 367–375E FLWEDQTLL	 --------- 372–380 TC
A*0201 UL27 208–288 SVYPYDEFV	 --------- 275–283 TC
A*0201 UL27 448–456E FLIAYQPLL	 --------- 443–451 TC
A*0201 UL39 425–433 RILGVLVHL	 --------- 430–438 TC
A*0201 UL40 184–192F ILIEGIFFA	 -----V--- 181–189 TS
A*0201 UL47 286–294 FLADAVVRL	 --V--I--V 289–297 TS
A*0201 UL47 374–382 ALLDRDCRV	 ---G----- 377–385 TS
A*0201 UL47 545–553 RLLGFADTV	 ----L---- 548–556 TS
A*2402 UL21 162–170F VYTPSPYVF	 A-------- 162–170 TS
A*2402 UL31 292–300 EYQRLYATF	 --------- 291–299 TC
A*2402 UL37 221–230 AYSLLFPAPF	 -------S-I 221–230 TS
A*2402 UL37 640–648 AYLPRPVEF	 ------I-- 640–648 TS
A*2402 UL46 226–234 AYVSVLYRW	 -------H- 226–234 TS
A*2402 UL54 504–512 KYFYCNSLF	 --------- 504–512 TC
A*2402 ICP4 1097–1106 LYPDAPPLRL	 PDG-----V- 1243–1252 TS
A*2902 UL25 170–179 SSGVVFGTWY	 ---------- 175–184 TC
A*2902 UL25 235–243 AVLCLYLLY	 --------- 240–249 TC
A*2902 UL26 22–30 YVAGFLALY	 --------- 22–30 TC
A*2902 UL26 326–334F YLWIPASHY	 --------- 328–336 TC
A*2902 UL27 295–303 VYMSPFYGY	 --------- 290–298 TC
A*2902 UL27 641–649 FTFGGGYVY	 -I------- 638–646 TS
A*2902 UL29 460–468 ALLAKMLFY	 --------- 460–468 TC
A*2902 UL29 895–903F YMANQILRY	 --------- 895–903 TC
A*2902 UL46 93–101 LASDPHYEY	 -------D- 93–101 TS
A*2902 UL46 126–134 AILTQYWKY	 ---A----- 126–134 TS
A*2902 UL46 224–232 LLAYVSVLY	 --------- 224–234 TC
A*2902 UL46 333–341 SIVHHHAQY	 --------- 333–341 TC
A*2902 UL47 508–516F ALATVTLKY	 --------- 511–519 TC
B*0702 ICP0 698–706E VPGWSRRTL	 A-A------ 742–750 TS
B*0702 UL21 382–390 VPRPDDPVL	 --A--E-T- 380–388 TS
B*0702 UL49 281–290 RPTERPRAPA	 --AG-AA-T- 276–285 TS
B*0702 US1 70–78 APRIGGRRA	 GDLR----R 62–70 TS
B*0702 US7 22–30 VVRGPTVSL	 --------- 22–30 TC
B*0702 US7 97–105 CPRRPAVAF	 --------- 97–105 TC
B*0702 US7 195–203 APASVYQPA	 G-S---T-G 195–203 TS
Polyclonal responder cells derived by cross-presentation and positive when screened with the indicated HLA alleles and ORFs were reactive with the indi-
cated HSV-1 peptides. AHLA cDNA used to screen HSV-1 ORFeome clone set. BHSV-1 ORF scoring positive that yielded a reactive peptide. CAmino acid 
numbers and HSV-1 sequences from GenBank NC_001806.1 scoring positive in IFN-γ ICC assay. DPredicted aa sequence and homologous portion of cor-
responding HSV-2 protein from GenBank NC_001798.1 (HSV-2). TC, type common epitope, identical between HSV-1 and HSV-2; TS, type specific.  
EThe HSV-2 homologs of these epitopes were previously described as CD8 epitopes with the same proven or probable HLA restriction using PBMCs from  
HSV-2–infected individuals and HSV-2 peptides (52–54). In the case of ICP0 742–750 of HSV-2, the epitope was previously assigned amino acids  
743–751 (93) based on our finding of an extra aa at the exon 1–exon 2 splice junction, based on cDNA sequencing, that is not present in GenBank  
NC_001798.1. FMultiple synthetic peptides were positive. For HLA-A*0201/UL40, 9-mer 184–192 and 10-mers 184–193 and 183–192 were positive. Simi-
larly, for HLA-A*2902/UL26, 10-mer 325–334 and 9-mer 326–334 were positive; for HLA-A*2902/UL29, 10-mer 894–903 and 9-mer 895–903 were positive; 
for HLA-A*2902/UL47, 10-mer 508–517 and 9-mer 508–516 were positive; and for HLA-A*2402/UL21, 10-mer 161–170 and 9-mer 162–170 were positive 
(Supplemental Figure 4; active 9-mers are shown, but the 10-mers are similar).
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Figure 8
Use of CD137 expression to enrich HSV-1–specif-
ic CD4+ T cells, and representative raw data from 
HSV-1 proteome-wide scan. (A) Top 2 panels show 
expression of CD137 by PBMCs after 20 hours of 
exposure to whole cell–associated UV-killed mock 
or HSV-1 lysate. Dot plots were gated for live, CD3+ 
cells in the lymphocyte forward/side scatter region. 
Numbers are percentages of cells in the upper-right 
quadrant. Small boxes indicate approximate gates for 
FACS. Bottom 6 panels show reactivity of polyclonal 
twice-expanded responder cell lines derived from 
CD3+CD4+CD137hi or CD3+CD4+CD137lo cells, after 
18 hours reexposure to autologous APCs and whole 
cell–associated UV-killed mock or HSV-1 lysate. 
APCs were CFSE dump-gated and responder cells 
stained intracellularly for IFN-γ and IL-2. Numbers 
are percentages of cells in indicated quadrants. (B) 
Representative screen of polyclonal HSV-1–reactive 
CD4+ cells to each HSV-1 protein or fragment, whole 
HSV-1–positive control, and irrelevant microbial 
negative control proteins. Data are mean of dupli-
cate assays. Red line is cutoff for positive responses 
calculated as described in Methods.
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immune responses or during reactivations in the chronic phase 
may also contribute correlates of severity and reactivation that 
could further influence vaccine design.
Interestingly, UL39 was a strong HSV-1 CD8 antigen in both 
humans and the one mouse MHC haplotype studied, H-2b. UL39 is 
a virulence factor involved in evading innate immunity and apop-
tosis (59), such that immune targeting of UL39 may be advanta-
geous to the host. The CD8 repertoire in infected C57BL/6 mice 
had a breadth of 19 HSV-1 epitopes. These were concentrated in 
only three ORFs, gB1 (gene UL27), UL39, and ICP8 (gene UL29) 
(60). The mice did not recognize immediate early HSV-1 poly-
peptides, while responses to ICP0, ICP4, ICP22, and ICP47 were 
detected in humans. In addition to MHC class I peptide binding 
preferences, these differences may reflect species-specific effects of 
HSV-1 HLA class I immune evasion genes (61) and the fact that 
the human exposure to HSV-1 antigen is chronic and intermit-
tent, while HSV-1 typically does not recur in mice. We conclude 
that study of adaptive immunity in the natural host is a necessary 
counterpoint to the powerful manipulative 
experiments that are possible in experi-
ment models of HSV-1 infection.
Several factors may have influenced our 
results. Our CD8 workflow used cross-pre-
sentation at the re-stimulation step, but 
then switched to direct present by aAPCs or 
peptide-loaded cells at the readout step. We 
observed that cross-presentation is efficient 
in presenting diverse HSV-1 proteins to 
CD8+ T cells. The HSV proteins ICP47 (gene 
US12) and vhs (gene UL41) inhibit direct 
presentation (30). We have previously re-
stimulated memory CD8+ cells using direct 
presentation by HSV-infected B lympho-
blastoid cell lines (B-LCLs), but this yielded 
a paucity of HSV-reactive CD8 clones reac-
tive only with membrane glycoproteins 
(62). HSV-infected fibroblasts failed in this 
endeavor. Direct presentation by infected 
DCs might uncover epitopes specific for this 
pathway, although HSV infection harms 
various DCs and renders them defective for 
antigen presentation (63–65). Future stud-
ies will compare direct and cross-presenta-
tion at the re-stimulation stage.
Expression of the HSV-1 proteome 
was not totally complete. Genes UL15.5, 
UL20.5, UL27.5, and UL43.5 are under 
development, as is the C-terminal approx-
imately 500 amino acids of the UL36 
protein. Genes predicted to be in-frame 
subsets of longer polypeptides were not included, but this will 
not lead to loss of potential epitopes. A poorly studied variable is 
allelic heterogeneity in HLA class I assembly with Chlorocebus sp. 
β2m in Cos-7 cells. We overexpressed HSV-1 ORFs in isolation 
in aAPCs, where intracellular trafficking and class I presentation 
could differ from the viral context. There were subtle differences 
in some of our HLA-C constructs from the HLA-A and -B vectors, 
but our method has achieved excellent HLA-C expression (66). 
There are interactions between HSV-1 proteins such as proteolysis 
and phosphorylation (1), and possibly species-specific host pro-
tein–HSV-1 protein interactions, that would differ between 
infected and transfected cells. In HSV-2 work using a genomic 
DNA library and Cos-7 transfection, we decoded the fine specific-
ity of each CD8 clone studied (52, 56, 67) and therefore believe 
such situations are rare for HSV. We focused on IFN-γ readouts 
of CD8+ T cell activation and proliferation to detect CD4+ T cell 
responses. With regard to effector cytokines, rare HSV-reactive 
T cells in PBMCs making TNF-α or IL-2 but not IFN-γ have been 
Figure 9
Graphical representation of CD4 and CD8 
reactivity to HSV-1 ORFs in PBMCs from 7 
HSV-1–infected individuals, indicated in the 
rows. Each column is an HSV-1 ORF. The 
ORFs are grouped by their kinetic expres-
sion during viral replication. White indicates 
no reactivity.
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described (54). In preliminary studies, substitution of TNF-α for 
IFN-γ ELISA did not uncover additional specificities (data not 
shown). We noted one HSV-seronegative individual with CD8 
responses to HSV-1 (participant 13 in Table 2). Further work will 
be required to determine whether reactivity can be confirmed at 
the epitope level, as has been done for HSV-2 (68).
We have extended the use of CD137 as an activation marker to 
two complex microbes for both CD4+ and CD8+ T cells. CD137 
Figure 10
Detection and enrichment of vaccinia-specific CD8+ and CD4+ T cells. (A) Left panels show expression of CD137 after 20 hours of exposure of 
CD8+ T cells to cross-presented mock or vaccinia antigen. Small boxes indicate approximate gates for FACS. Numbers are percent of total gated 
live CD3+ lymphocytes in each quadrant. Right panels show IFN-γ expression by bulk, expanded CD8+ CD137hi or CD137lo cells in response to 
exposure to autologous B-LCLs in the absence or presence of vaccinia infection, or positive control stimulus. Numbers are percentages of gated 
live, CD3+ lymphocytes in each quadrant. (B) Cytolytic activity of bulk, expanded CD8+CD137hi cells to autologous or allogeneic APCs with or 
without vaccinia infection. (C) Left panels show expression of CD137 by CD4+ T cells after 20 hours of exposure of PBMCs to UV-inactivated, 
cell-associated mock or vaccinia antigen. Small boxes indicate approximate gates for FACS. Numbers are percentages of gated live, CD3+ lym-
phocytes in each quadrant. Right panels show IFN-γ and IL-2 expression of polyclonal expanded CD4+ CD137hi or CD137lo cells to autologous 
APCs and mock or vaccinia antigen. APCs were CFSE dump-gated. Numbers are percentages of live, CD4+ cells in each quadrant.
technical advance
668	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 122   Number 2   February 2012
mediates a strong co-stimulatory signal to T cells. Thus, use of 
anti-CD137 to detect and purify antigen-reactive cells may assist 
their downstream expansion. Our data are consistent with some 
level of bystander CD137 expression, as the level of reactivity with 
whole HSV-1 among expanded CD137hi cells varied between 4% 
and 45%. Enrichment was better for CD4 cells. We cannot be sure 
that all memory HSV-reactive cells upregulated CD137. CD137 is 
similar in this regard to other molecules used for enrichment, such 
as CD134, CD154, and captured IFN-γ (69).
In summary, the T cell response to a complex and serious patho-
gen with a large genome, HSV-1, has been decoded with a linked 
set of cellular and molecular tools to reveal novel candidate vaccine 
antigens. We have preliminarily identified the proteins encoded 
by genes UL39 and UL46 as having high population prevalence of 
coordinated CD8 and CD4 responses and plan to study larger, 
defined populations to refine these conclusions. Cross-presenta-
tion followed by CD137-based selection also effectively enriches 
rare CD8+ cells specific for vaccinia virus, an effective live virus vac-
cine. CD137 is also suitable for enrichment of CD4+ T cells reactive 
with whole microbe preparations, as demonstrated for both HSV-1 
and vaccinia virus. Our flexible gene cloning format allows inte-
grated, efficient study of both CD8 and CD4 responses after one 
round of PCR-based cloning of microbial ORFs. Use of appropri-
ate initial re-stimulation conditions, CD137 as a flexible selection 
marker, and the genomes and complete genome-covering ORF sets 
now available for Mycobacterium tuberculosis, Plasmodium falciparum, 
and other agents should speed comprehensive definition of T cell 
responses and vaccine design.
Methods
Participants and specimens. Healthy adults with HSV-1 infection were recruit-
ed at the University of Washington Virology Research Clinic. Participants 
were antibody negative for HIV-1. HSV-1 and HSV-2 infections were docu-
mented with type-specific serum immunoblot (70). Vaccinia immune 
status was derived from history of vaccinia vaccination. None of the par-
ticipants had an oral or genital recurrence or received anti- herpesviral 
medication at the time of lymphocyte collection. The collection of PBMCs 
from vaccinia-immune individuals has been documented (71). Peripheral 
venous blood was collected with heparin and processed by Ficoll density 
gradient centrifugation (72). A 150-ml blood sample allowed CD8 and 
CD4 analyses for HSV-1. PBMCs were cryopreserved until use.
HLA typing. HLA at A and B loci was typed at the Puget Sound Blood 
Center, Seattle, Washington. When 2 digits followed by xx or 4 digits are 
reported, low or high resolution typing was done and the old nomencla-
ture used (73). HLA-C was typed by Dan Geraghty at the Fred Hutchin-
son Cancer Research Center by sequencing exons 2 and 3. Ambiguous 
HLA-C alleles are reported to 4 digits (predicted amino acid sequence) 
using the older nomenclature if there are only two possibilities. Some 
HLA-C alleles are reported using the new G nomenclature (http://hla.
alleles.org/alleles/g_groups.html) when there are multiple possible 
amino acid sequences (73).
Virus and cell culture. HSV-1 strain E115 (74) and HSV-2 strain 333 (75) 
were grown and titered (62) on Vero cells (ATCC). Vaccinia strain WR was 
grown and titered as described previously (76). Viral antigens for CD4+ cell 
stimulation and readout assays were diluted sonicates of Vero (HSV-1) or 
BSC40 (vaccinia) harvested by scraping when 80%–100% of the monolayer 
showed cytopathic effect and treated with UV light to eliminate infec-
tious virus (72, 77). HeLa and Cos-7 cells (ATCC) were cultured in DMEM. 
B-LCLs were immortalized from PBMCs using EBV strain B95-8 (62) and 
are permissive for HSV infection (78). Continuous cell lines were Myco-
plasma negative (Lonza). moDCs were cultured from adherent or CD14 
positively selected (Miltenyi) PBMCs using media, conditions, and recom-
binant human GM-CSF and IL-4 as described previously (53). Media (72, 
79) used 10% Fetalclone III (Fisher) instead of FCS.
Figure 11
Schematic overview of the high-throughput T cell anti-
gen discovery pathway. See text for details. In this 
report, the microbe (left) was a virus, HSV-1, but the 
workflow can also be adapted to bacteria or parasites. 
A microbial ORF library is initially cloned in a flexible 
format and subcloned (not shown) into both a custom 
protein expression vector for CD4 assays and a cus-
tom transient expression vector for CD8 assays. The 
CD4 workflow (top) stimulates PBMCs with whole 
killed microbe and detects and isolates microbe-
specific CD4+ T cells based on differential CD137 
expression followed by expansion. The polyclonal 
CD4+ responder cells are then assayed against the 
protein library made in vitro from the secondary pro-
tein expression clone set. The CD8 workflow (bottom) 
uses cross-presentation by microbial antigen-laden 
DCs to stimulate CD8+ T cells from PBMCs. After 
CD137-based selection and expansion, effector cells 
are assayed for reactivity with panels of person-spe-
cific aAPCs made by co-transfection of Cos7 cells 
with participant HLA class I cDNA and the transient 
transfection microbial ORF set. The integrated assays 
assign each ORF a yes/no result for each participant 
for CD4+ and CD8+ T cells (turquoise).
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Enrichment and expansion of virus-reactive T cells from PBMCs. For HSV-1–
specific CD8+ T cell enrichment, HeLa cells, seeded 1–2 days previously in 
6-well plates at 3 × 105 cells/well and used at 80%–90% confluence, were 
infected with HSV-1 at an MOI of 5, or a similar dilution of mock virus, for 
30 minutes with rocking in serum-free medium at 37°C, 5% CO2, followed 
by addition of complete medium. At 18 hours, a cytopathic effect was vis-
ible by microscopy. Cells were recovered by 20 mM EDTA and scraping, 
washed in TCM, resuspended at 2 × 106/ml in TCM, plated in a 6-well 
plate, and exposed to UV radiation (Stratalinker XL1000, Agilent, 180,000 
microjoules). moDCs were similarly recovered from their culture wells, 
washed, and resuspended at 2 × 106/ml in TCM and plated at 100 μl/well 
in 48-well plates. HeLa debris (100 μl/well, equivalent to 2 × 105 cells/well 
prior to UV) was added for a moDC/HeLa ratio of 1:1 for 5 hours at 37°C, 
5% CO2. CD8+ T cells were negatively selected from autologous PBMCs 
(Miltenyi) and added (1 × 106/well in 300 μl) to the antigen-loaded moDCs 
for a responder/DC ratio of 10:1 in a final volume of 500 μl TCM/well. 
Antigen loading and stimulations typically involved 15–20 identical wells/
person. Vaccinia-specific CD8+ T cells were restimulated by cross-presen-
tation as described for T cell clones (80), except that bulk PBMC-derived 
CD8+ T cells were used as responders. The remainder of the procedure 
matched that for HSV-1.
Stimulation was for 20 hours at 37°C, 5% CO2. Cells were pooled and 
stained with 7-AAD, anti-CD3–PE, anti-CD8α–FITC, and anti-CD137–
allophycocyanin (BD) for 30 minutes at room temperature in 50 μl TCM. 
After 2 washes, cells were resuspended in 1 × 107/ml in TCM. FACSAria II 
(BD) FACS used initial gating of live CD3+ lymphocytes. All available CD8+ 
CD137hi cells were collected, as was a fraction of the abundant CD137-
negative cells. Sorted cells were washed and plated in bulk with 1.5 × 105 
allogeneic 3,300 rad–irradiated PBMCs and 1.6 μg/ml PHA-P (Remel) in 
200 μl TCM in a 96-well U-bottom plate. Natural hIL-2 (32 U/ml, Hema-
gen) was added on day 2 and maintained for 14–16 days, typically yielding 
1 × 106 to 10 × 106 cells. A portion of the output cells from the first expan-
sion were bulk stimulated with anti-CD3 mAb, feeder cells, and recombi-
nant hIL-2 (79). This typically yielded a 1,000-fold cell increase in 14 days 
(81). Frozen sister aliquots of expanded cells were thawed for downstream 
assays. Reexpansion was not required.
Enrichment of virus-specific CD4+ T cells began with addition of UV-
inactivated, cell-associated HSV-1 or vaccinia (MOI of 1 prior to inacti-
vation) to 2 × 106 PBMCs per well of 24-well plates in 2 ml TCM. This 
HSV preparation has been proven to contain nonstructural proteins 
such as the UL50-encoded enzyme, and structural proteins (82). Cultures 
were initiated from 15 × 106 to 20 × 106 PBMCs. After 20 hours, cells 
were stained as above, but anti-CD4 was substituted for anti-CD8α. Live 
CD3+CD4+CD137+ cells, and a portion of the CD3+CD4+CD137– cells, were 
sorted and expanded in bulk as above.
HSV-1 ORFeome. Total DNA was prepared from cells infected with HSV-1 
strain 17+ (14) using the QIamp DNA Blood Mini Kit (QIAGEN) using 
the cultured cell instructions. PCR primers were designed (Supplemental 
Table 1) to amplify each annotated ORF in HSV-1 (GenBank NC_001806). 
Whenever possible, full-length ORFs were amplified. For ICP0, each exon 
was amplified independently. Since UL15 has an intron, its entry vector was 
generated using a cDNA clone as PCR template. Nomenclature was from 
a standard reference (1). In some cases, long ORFs were amplified as frag-
ments, usually overlapping by several amino acids (Supplemental Table 1). 
These were labeled as fragment A (frag A), etc., in the N- to C-terminal 
direction. In other cases, both a full-length clone and an internal fragment 
or fragments were separately cloned; the first internal fragment is labeled 
as frag A if it starts near the N terminus and frag B if not. ORFs that are 
internal to, in-frame with, and therefore have polypeptide sequences iden-
tical to fragments of longer ORFs, such as ORF UL26.5 within UL26 (1), 
were separately cloned in some instances but are not separately reported 
(see below). For each gene or fragment, both primers had a 5ʹ extension to 
allow recombinase-mediated integration into pDONR207 or pDONR221 
(Invitrogen), yielding vectors termed pENTR207-gene X or pENTR221-
gene X. Invitrogen reagents were used for recombination. Plasmids recov-
ered from candidate bacterial colonies were evaluated by restriction endo-
nucleases and/or sequencing.
Vector pDEST103, for CD8 work, accepts DNA inserts from either 
pDONR207 or pDONR221, and expresses polypeptides of interest 
such that EGFP is at the N terminus of a fusion polypeptide. To create 
pDEST103, peGFP-C1 (Clontech) was linearized with XhoI, blunt-ended 
with T4 DNA polymerase and dNTPS, dephosphorylated with calf intes-
tinal alkaline phosphatase, and gel-purified. Reading frame cassette A 
(Invitrogen) was ligated with T4 DNA ligase into peGFP-C1. After selec-
tion with chloramphenicol and kanamycin in E. coli strain ccdB survival 
2 T1R, intermediary vector pDEST102 was recovered, and the orientation 
of the cassette was confirmed by sequencing. pcDNA3.1(+) (Invitrogen) 
was digested with NheI and HindIII. pDEST102 was similarly digested, and 
the insert, comprising EGFP and cassette A with termini, was gel purified 
and ligated into digested pcDNA3.1(+), creating pDEST103. pDEST103 
expressed the ccdB-encoded protein and was selected with ampicillin and 
chloramphenicol in ccdB survival E. coli. The identity of pDEST103 was con-
firmed by sequencing through att recombination sites, EGFP, and flank-
ing regulatory regions. HSV-1 inserts were transferred from either of the 
pENTR series vectors (above) to pDEST103 with LR Clonase II (Invitrogen) 
and selected using ampicillin in E. coli DH5α, yielding pEXP103-gene X 
vectors. Candidate pEXP103-gene X expressing HSV-1 polypeptides were 
sequenced through their EGFP-HSV junctions at the N termini of the HSV 
polypeptide, and through the C termini insert-vector junctions. The fusion 
polypeptides are predicted to encode EGFP, followed by peptide SGLR-
CRITSLYKKAGF, followed by the HSV-1 polypeptide of interest. DNA 
was prepared using anion exchange (QIAGEN), measured at OD260 (Nano-
drop), and diluted in water (100 ng/μl) for transfection.
Expression of each HSV-1 ORF was checked by transfection of Cos-7 cells 
cultured in 96-well flat-bottom plates as described previously (81) with 100 
ng/well DNA. Forty-eight hours later, cells recovered by trypsinization were 
stained with Violet LIVE/DEAD (Invitrogen) and were analyzed for EGFP 
by flow cytometry after gating on live cells. For protein gD1, pEXP103-US6 
expression was confirmed with a mAb and flow cytometry as described 
previously (83). For protein gB1, pEXP103-UL27 expression was confirmed 
using the same technology, except that mAb H1817 (Novus) was used at 
5 μl/tube as the primary antibody and PE-conjugated goat anti-mouse IgG 
(Invitrogen) was used at 1 μl/tube as secondary antibody.
Each predicted HSV-1 polypeptide from the pENTR series (above) was 
separately subcloned into custom vector pDEST203 designed for in vitro 
protein expression and CD4 research. For construction of pDEST203, 
pIVEX2.4d (Roche) was digested with XhoI, blunt-ended with T4 DNA 
polymerase and dNTPs, dephosphorylated, and ligated with the read-
ing frame B cassette (Invitrogen). Colonies were selected in ccdB survival 
E. coli as above but with ampicillin and chloramphenicol. A sequence-
confirmed correct plasmid was termed pDEST203. pDEST203 has a T7 
promoter, a transcriptional unit encoding 6-histidine (6-His) fused to 
the HSV-1 polypeptide, attR recombination sites, and features suitable 
for in vitro transcription/translation. HSV-1 inserts from pENTR207 or 
pENTR221 were moved to pDEST203 using LR Clonase II to generate the 
pEXP203-ORF series. The left and right vector insert junctions of each 
pEXP203-ORF plasmid were sequenced to confirm identity and in-frame 
fusion with 6-His. Each pEXP203 construct encodes MSGSHHHHHHSS-
GIEGRGRLIKHMTMASRLESTSLYKKAGF at the N terminal, followed 
in-frame by the HSV-1 polypeptide. For expression, pEXP203 plasmids 
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were prepared from a 3-ml ampicillin culture of transformed E. coli using 
a silica method (QIAGEN) and mass determined by spectrophotometry. 
Proteins were expressed using 50 μl volumes of the Expressionway E. coli 
system (Invitrogen). To check expression, 1 μl of reaction product was 
spotted onto nitrocellulose membranes (Whatman), air dried, blocked 
with 1% blocking reagent (Roche) diluted in TBS (50 mM Tris, 150 mM 
NaCl, pH 7.5), probed with anti–6-His mAb (Roche) diluted 1:500 in TBS–
0.1% Tween 20 (TBS-T) (Roche), washed with TBS-T, incubated with HRP-
conjugated anti-mouse IgG (Promega) diluted 1:2,500 in TBS-T, washed 
with TBS-T, and developed with TMB substrate (Promega). Proteins fail-
ing to display a spot indicating anti–6-His binding were re-synthesized. 
For HSV-1 protein VP22 (gene UL49), expression was checked by triplicate, 
3-day [3H]thymidine proliferation assay using cornea-derived CD4+ clone 
9447.28 specific for HSV-1 VP22 aa 199–211 (18) as responders (2 × 104/
well), autologous 3,300 rad–γ-irradiated PBMCs as APCs (105/well), and 
HSV-1 VP22 or controls expressed in the pEXP203 system.
HLA cDNA cloning. HLA class I cDNAs for A*0101, A*0201, A*2902, 
B*0702, B*0801, B*4402, and B*5801 are documented (52, 56, 71, 84). 
Cloning of HLA-A*2402, -A*2601, and -A*6801 used 5ʹ primer CCGCC-
GCTAGCATGGCCGTCATGGCGCCCCGA and 3ʹ primer CCGCCCTC-
GAGTCACACTTTACAAGCTGTG. Cloning of HLA-B*1516, -B*3503, 
-B*5101, and -B*5801 used 5ʹ primer CCGCCGCTAGCATGCGGGT-
CACGGCGCCCCGAACCG and 3ʹ primer CCGCCCTCGAGTCAAGCT-
GTGAGAGACACATCAG. Cloning of HLA-Cw0704 used 5ʹ primer 
CCGCCTGCTAGCATGCGGGTCATGGCGCCCCGAG and 3ʹ primer 
CCGCCCGTCTCGAGTCAGGCTTTACAAGTGATGAGAGAC. Cloning 
of HLA-Cw0102, -Cw0202, -Cw0401, -Cw0501, -Cw0701, -Cw0702, and 
-Cw1402 used 5ʹ primer TATAAAGCTTTTCTCCCCAGACGCCGAGA 
and 3ʹ primer ATATGCGGCCGCGTCTCAGGCTTTACAAGCGA (66). 
For new alleles, RNA was prepared from PBMCs or B-LCLs (79) (RNeasy 
kit, Invitrogen). cDNA synthesis used random hexamer primers (HLA-A, 
-B, and -Cw0704) or oligo-dT (other HLA-C alleles) and Superscript II 
(Invitrogen). PCR used the above primer pairs (bold NheI and XhoI sites 
for HLA-A, -B, and -Cw0704; HindIII and NotI for other HLA-C; additional 
distal non-HLA sequences are shown in italics; HLA-specific sequences 
in regular type with ATG start codons are underlined for HLA-A, -B, and 
-Cw0704). PCR amplicons at the expected MW were digested with the 
restriction enzymes listed and cloned into pcDNA3.1(+) (Invitrogen) 
(HLA-A, -B, and -Cw0704) or pcDNA3.1/V5-His TOPO (Invitrogen) (other 
HLA-C). cDNA clones with 100% sequence matches (85) were prepared by 
anion exchange (QIAGEN). For validation of expression, Cos-7 cells were 
transfected with plasmid cDNA and FuGENE 6 (Boehringer Mannheim-
Roche) for 48 hours, trypsinized, and surface stained for flow cytometry 
with anti-HLA mAb (A*0101: 0544HA; A*0201: MA2.1, ref. 86; A*2402: 
0497HA; A*2601: 0544HA; A*2902: 0334HA; B*0801: 0059HA; B*1516: 
0044HA; B*3503: 0789AHA; B*4402: 0786BHA; One Lambda, except 
MA2.1 as described in ref. 56). Isotype-appropriate fluorochrome-labeled 
polyclonal antibodies were used to detect primary antibody binding (81). 
Negative controls were Cos-7 cells stained with secondary antibody only, 
nontransfected Cos-7 cells with both antibodies, and HLA-mismatched 
B-LCLs; positive controls were HLA-matched B-LCLs. In some situations, 
HLA alleles were matched to participants based on low-resolution typing 
and knowledge of the most prevalent HLA allelic subtypes. Specifically, for 
participant 2 with HLA-B*07 and -B*08, we used the most likely alleles, 
B*0702 and B*0801; for participant 5 with HLA-A*01 and -B*08 and 
B*51, we used A*0101, B*0801, and B*5101; and for participant 6 with 
A*24, we used A*2402. For one participant at each locus, only one genome 
scan was done for CD8 responses due to homozygosity or near homozy-
gosity. Specifically, for participant 7, who had HLA-A*0220 and -A*0224 
(each differing from A*0201 at a single amino acid), we used A*0201 only. 
Participant 6 had both B*3503 and B*3502 (differing by 3 amino acids 
from B*3503), of which only B*3503 was studied, and was homozygous for 
HLA-C*04G1, for which Cw0401 was studied. Participant 4 had A*2901, 
but we used A*2902 differing at one amino acid.
ORFeome CD8 screens. Cos-7 cells were plated in 96-well flat plates as 
described previously (56) and 24 hours later were simultaneously trans-
fected with 50 ng HLA cDNA and 150 ng/well pDEST103-based HSV-1 
construct. Each HSV-1 ORF or fragment was assayed in duplicate. Negative 
controls were pDEST103 mono-transfected. After 48 hours, bulk polyclonal 
CD8+ effector cells (above) were added at 5 × 104 to 10 × 104/well in 200 μl 
fresh TCM. After 16–24 hours, supernatants were collected and stored at 
–20°C. T cell activation was detected by supernatant ELISA for IFN-γ (56).
ELISA data were designed to classify each HSV-1 ORF/HLA transfec-
tion combination as positive or negative for each responder T cell line. 
For an ORF to be considered positive, we required that both individual 
OD450 readings were 0.08 or greater for every screen, except for one with 
higher background, where the threshold was set at 0.1. For ORFs screened 
as more than one fragment, or both a full-length and one or more internal 
fragments or separately annotated but in-frame genes, or exon by exon, 
the major ORF was considered the fundamental unit of analysis and was 
considered positive if one or more fragment(s) scored positive. Analyses 
grouped proteins by the kinetics of gene expression in the context of infect-
ed cells or by structural or functional biology from reviews (1) and primary 
literature, as well as by the presence or absence from virions (51).
ORFeome CD4 screens. Bulk-expanded HSV-1–reactive CD4+ T cell lines were 
tested for proliferative responses to individual HSV-1 proteins as described 
for vaccinia (87, 88). Briefly, 5 × 104 to 10 × 104 autologous γ-irradiated 
(3,300 rad) PBMCs, 3 × 104 bulk responder cells, and recombinant HSV-1 
proteins (above) diluted 1:5,000 were plated in duplicate in 200 μl TCM in 
96-well U-bottom plates. Negative controls included similar dilutions of 
the in vitro transcription/translation products of plasmids encoding Fran-
cisella tularensis proteins, empty pDEST203, or no DNA. F. tularensis ShuS4 
molecular clones of genes 1208, 1127, 1305, 7056, 1306, 1314, 1961, 5396, 1852, 
1254, 1729, 1695, 1544, 1835, and 1963 in vector pXT7 (89) were maintained 
in E. coli under kanamycin selection. Protein was synthesized as described 
for HSV-1. UV-treated HSV-1 and mock virus were positive and negative 
controls. [3H]thymidine incorporation was measured after 3 days (47). The 
criteria for designating an HSV-1 ORF or fragment as positive used the nega-
tive controls (n = 30) and was set as the mean plus 3.09 times the SD of the 
negative controls (n = 30) (47) for a 1-tailed false discovery rate of 0.1%.
ICC. The reactivity of T cell responder cultures was tested by ICC as 
described previously (87). The format for checking CD8 reactivity with 
whole virus involved infected autologous B-LCLs with mock virus, HSV-1, 
HSV-2, or vaccinia for 18 hours at MOI 5, washing, and coculturing 2 × 105 
B-LCLs with 2 × 105 responder T cells in 1 ml TCM. For CD4 reactivity, 
2 × 105 autologous, CFSE-labeled PBMCs were cocultured with 2 × 105 
responder T cells and UV-treated HSV-1, HSV-2, vaccinia, or mock virus 
at 1:100 dilution in 1 ml TCM. For peptides, responder T cells were cocul-
tured with equal numbers (~105) of CFSE pre-labeled autologous B-LCLs 
and 1 μg/ml peptide or an equivalent volume of DMSO as negative control. 
Either staphylococcal enterotoxin B (SEB, 1 μg/ml, BD) or PMA and iono-
mycin (88) were used as positive control. Anti-CD28 and anti-CD49d were 
added at assay setup, and brefeldin A was used to reduce cytokine secretion. 
Cells were surface stained for CD8 or CD4 as appropriate, permeabilized, 
and stained intracellularly for IFN-γ, and in some cases also for TNF-α 
and IL-2 (80). After appropriate washes and fixation, CFSE-negative cells 
in the lymphocyte forward and side scatter gates were analyzed by flow 
cytometry for binding of fluorochrome-labeled antibodies. For peptides, 
responses were considered positive if a discrete group of IFN-γ–expressing 
cells was observed and the percentage of IFN-γ+ cells was greater than 2× 
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DMSO background. Low-positive peptide responses were repeated at least 
once including new negative controls, and only repeatedly reactive peptide 
responses were considered positive and are reported herein.
Cytolysis assays. The cytolytic activity of sorted, bulk, polyclonally expanded 
T cell responder cultures was tested in 51Cr release assays (90). Briefly, 
target cells were created by infection of autologous or HLA class I–mis-
matched allogeneic B-LCLs with HSV-1 or vaccinia at an MOI of 5 for 18 
hours (90) while labeling with 51Cr. Washed target cells (2 × 103/well) were 
cocultured in triplicate in 96-well U-bottom plates with a 40-fold excess of 
responder cells for 4 hours at 37°C, 5% CO2. Media or 5% IGEPAL (Sigma-
Aldrich) were used for spontaneous and total 51Cr release, respectively. 
Thirty microliters of supernatant was counted using Lumaplates and a 
TopCount (Packard). Data are reported as percent specific release (90); 
spontaneous release (90) was typically less than 20%.
ELISPOT. For direct testing of PBMCs ex vivo, duplicate IFN-γ ELISPOT 
was done as described previously, except that unmanipulated PBMCs were 
used (53). Thawed PBMCs were tested at 7.5 × 105/well. Stimuli were HSV-1 
peptides (1 μg/ml, n = 41), 0.1% DMSO negative control, and UV-killed 
HSV-1 at 1:100 dilution as positive control. Five peptides were omitted: 
HSV-1 UL53 201–209 (HLA-A*0101 restricted), UL26 326–334 and UL27 
641–649 (HLA-A*2909 restricted), and US7 22–30 and ICP0 698–706 
(HLA-B*0702 restricted). Potential positives were manually reviewed using 
high-density images. Peptides with more than 10 SFU per 106 PBMCs and 
greater than 2× DMSO background were considered positive.
HSV-1 peptides. The predicted amino acid sequences for HSV-1 ORFs or 
fragments that were reactive in CD8 ORFeome analyses were submitted 
with the restricting HLA class I alleles to binding prediction algorithms 
(91). Top-ranking 9-mers or 10-mers were synthesized with native termini, 
usually 3–10 per ORF per HLA allele (Sigma-Aldrich). We also purchased 
peptides gD1 (gene US6) 77–85 (SLPITVYYA), 94–102 (VLLNAPSEA), and 
302–310 (ALLEDPVGT), reported to bind HLA-A*0201 tightly and to be 
A*0201-restrcited epitopes in gD1 (16). Peptide HSV-1 UL25 367–375 was 
made as described previously (54). Throughout, amino acid 1 refers to the 
genomic ATG encoding methionine, rather than alternative numbering 
schemes (16). The manufacturer characterized peptide MW by mass spec-
troscopy. Peptides were diluted to 10 mg/ml in DMSO, stored at –20°C, 
and further diluted in TCM.
Statistics. For CD4 ORFeome screens, HSV-1 ORFs with mean cpm values 
above the mean plus 3.09 times the SD for negative controls were consid-
ered positive for a 1-tail false discovery rate of 0.1% (87). This q statistic for 
false discovery rates is generally considered to be analogous to the P value; 
in this case 0.1% corresponds to P of 0.001. For CD8 ORFeome screens, the 
mean background raw IFN-γ ELISA OD450 values were typically 0.05 and 
were normally distributed. ORFs for which each duplicate well yielded an 
IFN-γ ELISA OD450 value greater than 2× the mean background value raw 
OD450 (typically 0.08) were considered positive.
Study approval. Healthy adults with HSV-1 infection or a history of vac-
cinia vaccination were studied under a protocol approved by the Univer-
sity of Washington IRB, Seattle, Washington, USA. Participants provided 
informed written consent.
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